Quinolinate-induced immune suppression in glioblastoma
Active Project Grant Awarded Last action
- Award ID
- R01NS129744
- Recipient
-
William Beaumont Hospital UEI KJWYBQN9STL7
- Awarding agency
-
National Institute of Neurological Disorders and Stroke
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,888,600
Award facts
- Assistance listing
- 93.853 Extramural Research Programs in the Neurosciences and Neurological Disorders
- Completion date 64% complete
- Place of performance
- Royal Oak, MI 48073, USA
Award details come from USAspending.gov.
Description
- Abstract
- Recent advancements using immune checkpoint inhibitors designed to target tumor-mediated immune tolerance have revolutionized cancer therapy. Unfortunately, these clinical successes have not translated to glioblastoma (GBM), which continues to be an invariably fatal malignancy with limited treatment options. One of the leading thoughts in the field explaining this lack of clinical benefit in GBM is that these agents are acting upon the wrong target. Tumor-associated macrophages (tams) appear to represent the primary immune cells contributing towards the immune suppressive microenvironment in GBM, vastly outnumbering t cell infiltration. Hence, there is considerable interest in developing therapeutic strategies designed to target M2 tams or revert their polarization to enhance antitumor immunity. We discovered the accumulation of quinolinate (QA), a downstream intermediate of tryptophan metabolism, as a previously undescribed metabolic node in GBM. Through a series of investigations, we went on to demonstrate the potent ability of QA to sculpt the GBM immune landscape by polarizing macrophages towards the immune suppressive M2 phenotype. Potent anti-tumor activity was observed when tested in GBM lines grown intracranially, supporting the therapeutic potential of targeting QA metabolism in GBM. In this proposal, we now seek to define mechanisms contributing towards QA-mediated macrophage polarization (aim 1), extend studies evaluating the immunologic/metabolic consequence of targeting QA in GBM (aim 2), and identify rational combinatorial strategies designed to exploit inhibition of QA-induced immune suppression (aim 3). If successful, these results would offer a previously unrecognized window into the complex metabolic interplay between tumor and immune cells in the GBM microenvironment, its functional consequence on immune suppression, and framework for the identification of novel therapeutic strategies in this aggressive malignancy with limited treatment options.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $380,000 | |
| Amendment | $380,000 | |
| Amendment | $368,600 | |
| Amendment | $380,000 | |
| Original award | $380,000 |
Quick answers
Who received award R01NS129744?
R01NS129744 was awarded to William Beaumont Hospital by National Institute of Neurological Disorders and Stroke (National Institutes of Health) on August 15, 2023.
How much is award R01NS129744 worth?
$1,888,600 has been obligated on R01NS129744.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award